Overall Fundamental outlook

Business Operations:

Sector: Basic Materials
Industry: Agricultural Inputs

Bayer CropScience Limited engages in the manufacture, sale, and distribution of insecticides, fungicides, herbicides, and various other agrochemical products and corn seeds in India, Germany, Bangladesh, and internationally. It provides medicines primarily in the therapeutic areas of cardiology, gynecology, diabetes, oncology, and ophthalmology; and computed tomography, X-Ray, and magnetic resonance imaging devices. In addition, the company offers consumer health products that are used as a daily health solution to treat minor illnesses, as well as sells and distributes hybrid seeds, such as corn and paddy. Further, it provides digital farming products comprising FarmRise and other digital applications, such as drones for spray services, etc., as well as provides various technologies, such as remote sensing, IoT sensors, GPS, artificial intelligence, and data analytics to monitor and manage crop growth, soil quality, weather patterns, and other factors. The company also exports its products. Bayer CropScience Limited was founded in 1863 and is based in Thane, India.

Revenue projections:

Revenue projections for BAYERCROP
Revenue projections for BAYERCROP

Investors may be wary of Bayer CropScience Limited as its revenues are expected to fall below the prior year's levels. A revenue decrease often leads to concerns about profitability, as it is likely to affect the company's bottom line, prompting investors to take a more cautious approach.

Financial Ratios:

currentRatio 2.011000
forwardPE 24.721855
debtToEquity 3.687000
earningsGrowth 0.493000
revenueGrowth 0.322000
grossMargins 0.379030
operatingMargins 0.130450
trailingEps 126.630000
forwardEps 0.000000

BAYERCROP's current ratio is 2.011, signaling that the company has sufficient cash reserves and current assets to cover its short-term debt obligations. This suggests financial stability, as BAYERCROP should not face any issues meeting its short-term liabilities with available resources.
BAYERCROP's Forward PE is in a favorable range, suggesting the stock is reasonably priced relative to its earnings. This indicates the stock is not overpriced, providing room for potential growth and making it an attractive option for investors looking for solid value and future upside.
Positive earnings and revenue growth for BAYERCROP suggest that the company is expected to grow its business. This trend reflects strong financial performance, with continued profitability and sales increases indicating a bright outlook for future expansion.

Price projections:

Price projections for BAYERCROP
Price projections for BAYERCROP

BAYERCROP's price has consistently remained near the lower edge of projections, suggesting that it is not fully meeting market expectations. This could indicate a need for improved performance or strategies to boost investor confidence.

Recommendation changes over time:

Recommendations trend for BAYERCROP
Recommendations trend for BAYERCROP


Recent analysis shows a strong buy bias for BAYERCROP, encouraging investors to view it as a solid investment option. The positive sentiment surrounding BAYERCROP suggests it could be an attractive place to allocate funds, motivating potential investors to consider the stock as a valuable part of their portfolio.